ArticleJournal of medical imaging (Bellingham, Wash.)2025
Physician-guided deep learning model for assessing thymic epithelial tumor volume.
Article in Journal of medical imaging (Bellingham, Wash.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The Response Evaluation Criteria in Solid Tumors (RECIST) relies solely on one-dimensional measurements to evaluate tumor response to treatments. However, thymic epithelial tumors (TETs), which frequently metastasize to the pleural cavity, exhibit a curvilinear morphology that complicates accurate measurement. To address this, we developed a physician-guided deep learning model and performed a retrospective study based on a patient cohort derived from clinical trials, aiming at efficient and reproducible volumetric assessments of TETs. Approach: We used 231 computed tomography scans comprising 572 TETs from 81 patients. Tumors within the scans were identified and manually outlined to develop a ground truth that was used to measure model performance. TETs were characterized by their general location within the chest cavity: lung parenchyma, pleura, or mediastinum. Model performance was quantified on an unseen test set of 61 scans by mask Dice similarity coefficient (DSC), tumor DSC, absolute volume difference, and relative volume difference. Results: We included 81 patients: 47 (58.0%) had thymic carcinoma; the remaining patients had thymoma B1, B2, B2/B3, or B3. The artificial intelligence (AI) model achieved an overall DSC of 0.77 per scan when provided with boxes surrounding the tumors as identified by physicians, corresponding to a mean absolute volume difference between the AI measurement and the ground truth of Conclusion: We have successfully developed a robust annotation workflow and AI segmentation model for analyzing advanced TETs. The model has been integrated into the Picture Archiving and Communication System alongside RECIST measurements to enhance outcome assessments for patients with metastatic TETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.